Potential Patient-Reported Toxicities With Disulfiram Treatment in Late Disseminated Lyme Disease
| Autor: | Raouf Ghozzi, Hugues Gascan, Alain Trautmann |
|---|---|
| Přispěvatelé: | Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Lannemezan, Jonchère, Laurent, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication 030106 microbiology disulfiram Double blind 03 medical and health sciences 0302 clinical medicine Lyme disease [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication Internal medicine Medicine ALCOHOL INGESTION risk Tick-borne disease lcsh:R5-920 business.industry benefit General Medicine Brief Research Report medicine.disease lyme disease 3. Good health LYME Clinical trial 030220 oncology & carcinogenesis Disulfiram Late Disseminated Lyme Disease business patient-reported adverse drug reactions lcsh:Medicine (General) medicine.drug |
| Zdroj: | Frontiers in Medicine, Vol 7 (2020) Frontiers in Medicine Frontiers in Medicine, 2020, 7, pp.133. ⟨10.3389/fmed.2020.00133⟩ Frontiers in Medicine, Frontiers media, 2020, 7, pp.133. ⟨10.3389/fmed.2020.00133⟩ |
| ISSN: | 2296-858X |
| DOI: | 10.3389/fmed.2020.00133/full |
| Popis: | International audience; Recently, disulfiram has been proposed as a promising treatment for people suffering from persistent symptoms of Lyme Disease. Disulfiram has several distinct molecular targets. The most well-known is alcohol dehydrogenase, a key enzyme for detoxifying the organism after alcohol ingestion. Other targets and modes of action of disulfiram, that may present problematic side effects, are less commonly mentioned. The French Federation against Tick Borne Diseases (French acronym, FFMVT), which associates three main Lyme patient organizations, MDs and PhDs, has recently been alerted to severe and persistent toxic events in a patient suffering from a late disseminated form of Lyme Disease following disulfiram intake. FFMVT reacted by launching a national call to examine whether other patients in France following a similar treatment could be identified, and what benefits, or side effects could be reported. The statements of 16 patients taking disulfiram have been collected and are presented here. Thirteen out of 16 patients reported toxic events, and seven out of 16 reported benefits for at least part of their symptoms. Based on the collected observations, it seems too early to promote disulfiram as a promising new treatment until the reasons underlying the reported toxicities have been explored, and the results of a well-conducted double blind clinical trial published. The importance of taking into account patient-reported outcomes in Lyme Disease is underlined by the present study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|